iRhythm Technologies, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. The filing describes iRhythm as a digital healthcare company providing remote cardiac monitoring through its Zio services. Results are unaudited. The filing does not provide specific numerical full-year revenue or earnings guidance.
Financial performance and liquidity
| Metric | Q1 2024 | Q1 2023 | Change / context |
|---|---|---|---|
| Revenue | $131.9 million | $111.4 million | Up 18%; management attributed growth mainly to higher service volume, with average selling price relatively stable. |
| Gross profit / margin | $87.5 million / 66.3% | $75.7 million / 67.9% | Gross profit up 16%; margin down about 1.6 percentage points as cost of revenue grew 24%. |
| Operating expenses | $125.7 million | $115.2 million | Up 9%; R&D rose 14% and SG&A rose 8%. |
| Operating loss / margin | $(38.1) million / (28.9)% | $(39.5) million / (35.5)% | Operating loss narrowed by $1.4 million. |
| Net loss | $(45.7) million | $(39.1) million | Loss increased, including a $7.6 million debt-extinguishment loss and higher interest expense. |
| Net loss per share | $(1.47) | $(1.29) | Basic and diluted. |
| Adjusted EBITDA (non-GAAP) | $(12.1) million | $(12.0) million | Approximately flat; excludes, among other items, stock-based compensation and debt-extinguishment loss. |
| Cash used in operating activities | $52.0 million | $30.8 million | Higher use was attributed mainly to receivables collection timing. |
| Cash and liquidity | $520.4 million cash and equivalents; $48.7 million marketable securities | At Dec. 31, 2023: $36.2 million cash and equivalents; $97.6 million marketable securities | Cash, equivalents and securities totaled $569.1 million at quarter-end; an additional $8.4 million was restricted cash. |
| Debt | $661.3 million principal; $644.1 million carrying amount | No 2029 Notes | New 1.50% convertible notes due September 2029; prior SVB and Braidwell facilities were repaid and terminated during Q1. |
Material changes and financing
- Revenue growth reflected increased Zio service volume. Cost of revenue rose faster than revenue, including higher labor costs and amortization related to Zio Monitor PCBAs and revenue-cycle software.
- SG&A increased, primarily due to third-party claims-processing fees; the prior-year quarter included $5.7 million of business-transformation costs that did not recur.
- On March 7, the company issued $661.3 million principal amount of 1.50% convertible notes due 2029, receiving approximately $643.6 million net proceeds. It used proceeds for capped calls costing $72.4 million, repayment and termination costs for Braidwell debt, a $25.0 million share repurchase, and general corporate purposes.
- The notes have an initial conversion price of approximately $147.22 per share. Capped calls have an initial cap price of $218.10 per share and are intended to reduce potential dilution or offset certain conversion payments, subject to the cap.
- The $25.0 million repurchase covered 229,252 shares at $109.05 per share. The company reported 31.1 million common shares outstanding at March 31.
Outlook, risks and unusual items
- Management said existing cash, cash equivalents, marketable securities and expected service revenue should meet liquidity needs for at least 12 months. It expects accounts receivable to move toward more normalized levels during Q2 2024 after a billing backlog was substantially cleared.
- A Change Healthcare cybersecurity incident disrupted the company’s third-party billing vendor’s processes, temporarily delaying billing and cash collections. The filing describes a collections delay, not a company-reported direct breach.
- Management expects cost of revenue and R&D expenses to rise in absolute dollars as the business grows and develops products; gross margin remains exposed to labor, materials, shipping, software amortization and inflation.
- Medicare represented 24% of revenue. CMS reimbursement rates for relevant monitoring codes changed effective January 1, 2024; the filing notes lower rates for services at the Deerfield location and warns that future reimbursement changes or commercial-payor negotiations could pressure results.
- Significant regulatory and legal matters include an FDA warning letter concerning Zio AT quality-system and reporting issues, ongoing DOJ subpoenas relating to products and FDA communications, a new securities class action, and a patent-infringement suit filed by Welch Allyn. The company disputes the claims where stated and says it is cooperating with authorities or will defend itself; outcomes are uncertain.
- Other risks include complex billing and claims audits, transition of claims processing from XIFIN to Omega, reliance on single-source suppliers, capacity to support growth, competition, data privacy and cybersecurity, and potential dilution or cash demands if convertible notes convert or become repayable. The company identifies the ongoing possibility of losses and does not assure future profitability.
- Management reported disclosure controls and procedures were effective at the reasonable-assurance level as of March 31, 2024, with no material change in internal control over financial reporting during the quarter.
Most important facts for investors to verify
- Whether revenue growth can continue while gross margin pressure and operating losses persist.
- Whether accounts receivable and cash collections normalize after the billing disruption, and whether the claims-vendor transition causes further delays or denials.
- The effect of 2024 Medicare reimbursement rates and any subsequent payor changes on realized revenue and margins.
- Cash consumption, planned investment needs, and the obligations and potential dilution associated with the $661.3 million convertible notes and capped calls.
- Developments and potential financial or operational consequences from FDA, DOJ, securities-litigation and patent matters.
- Progress on Zio Monitor commercialization, manufacturing capacity and supply availability, including single-source components.